Rhenman & Partners Asset Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,000	Closed	-$41K	–	117
2017 Q2	$41K	Hold	25,000	–	–	0.01%	108
2017 Q1	$85K	Hold	25,000	–	–	0.01%	104
2016 Q4	$130K	Sell	25,000 -12,500	-33%	-$216K	0.02%	106
2016 Q3	$945K	Hold	37,500	–	–	0.15%	89
2016 Q2	$927K	Sell	37,500 -16,875	-31%	-$477K	0.16%	88
2016 Q1	$1.57M	Buy	54,375 +23,125	+74%	+$627K	0.31%	80
2015 Q4	$1.16M	Hold	31,250	–	–	0.18%	94
2015 Q3	$1.52M	Sell	31,250 -46,200	-60%	-$3.23M	0.24%	85
2015 Q2	$5.34M	Sell	77,450 -10,214	-12%	-$473K	0.64%	54
2015 Q1	$3.13M	Buy	87,664 +37,664	+75%	+$1.11M	0.53%	65
2014 Q4	$632K	Hold	50,000	–	–	0.18%	84
2014 Q3	$768K	Buy	50,000 +12,500	+33%	+$263K	0.22%	92
2014 Q2	$1.02M	Buy	37,500 +22,760	+154%	+$562K	0.3%	88
2014 Q1	$395K	Sell	14,740 -172	-1%	-$4.37K	0.12%	91
2013 Q4	$366K	Buy	+14,912	New	+$384K	0.14%	83

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Rhenman & Partners Asset Management's ANTH Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2017, closing a stake of 25,000 shares — an estimated $41K sold.

Rhenman & Partners Asset Management first reported a position in ANTH in Q4 2013 and held it in 15 quarters. The position peaked at $5.34M in Q2 2015. 35 funds tracked by Wall St. Rank hold ANTH as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 25,000 Anthera Pharmaceuticals, Inc. shares in Q3 2017, an estimated $41K.
Rhenman & Partners Asset Management first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2013 and held it in 15 quarters.
Rhenman & Partners Asset Management's Anthera Pharmaceuticals, Inc. position peaked at $5.34M in Q2 2015.
35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.